Edition:
India

Kala Pharmaceuticals Inc (KALA.OQ)

KALA.OQ on NASDAQ Stock Exchange Global Select Market

14.20USD
23 Feb 2018
Change (% chg)

$0.13 (+0.92%)
Prev Close
$14.07
Open
$14.11
Day's High
$14.52
Day's Low
$13.91
Volume
32,164
Avg. Vol
89,213
52-wk High
$26.74
52-wk Low
$11.81

Latest Key Developments (Source: Significant Developments)

Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals
Saturday, 13 Jan 2018 

Jan 12 (Reuters) - Kala Pharmaceuticals Inc ::ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10.  Full Article

Kala Pharmaceuticals Announces Topline Results For Two Phase 3 Trials Of Kpi-121
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FOR TWO PHASE 3 TRIALS (STRIDE 1 AND STRIDE 2) OF KPI-121 0.25% IN DRY EYE DISEASE.KALA PHARMACEUTICALS INC - KPI-121 0.25% WAS WELL-TOLERATED WITH ELEVATIONS IN IOP SIMILAR TO PLACEBO.KALA PHARMACEUTICALS INC - IN STRIDE 1 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS- OCULAR DISCOMFORT SEVERITY AT DAY 15 IN ITT POPULATION SHOWED IMPROVEMENT BUT DID NOT REACH STATISTICAL SIGNIFICANCE IN STRIDE 2.KALA PHARMACEUTICALS INC - IN STRIDE 2 TRIAL, STATISTICAL SIGNIFICANCE WAS ACHIEVED FOR PRIMARY SIGN ENDPOINT.KALA PHARMACEUTICALS INC - WILL CONTINUE TO ANALYZE RESULTS OF BOTH PHASE 3 TRIALS.  Full Article

Kala Pharmaceuticals Announces NDA For Inveltystm Accepted By U.S. FDA
Friday, 5 Jan 2018 

Jan 5 (Reuters) - Kala Pharmaceuticals Inc ::KALA PHARMACEUTICALS ANNOUNCES NEW DRUG APPLICATION FOR INVELTYSTM (KPI-121 1%) HAS BEEN ACCEPTED FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION.KALA PHARMACEUTICALS INC - BRAND NAME FOR KPI-121 1%, INVELTYS, HAS BEEN CONDITIONALLY APPROVED BY FDA.KALA PHARMA-FDA INDICATES APPLICATION FOR INVELTYSTM SUFFICIENTLY COMPLETE TO PERMIT SUBSTANTIVE REVIEW,SET PDUFA TARGET ACTION DATE OF AUGUST 24,2018​.  Full Article

Kala Pharmaceuticals reports Q3 loss per share $0.56
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Kala Pharmaceuticals Inc :Kala Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.56.Kala Pharmaceuticals - ‍Top-line results from phase 3 clinical program for KPI-121 0.25% in patients with dry eye disease are expected by end of 2017​.Kala Pharmaceuticals Inc - ‍Expects that its existing cash on hand will enable it to fund operations through Q2 of 2019​.  Full Article

Kala Pharmaceuticals submits new drug application for Inveltystm
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Kala Pharmaceuticals Inc :Kala pharmaceuticals submits new drug application to U.S. Food and Drug Administration for Inveltystm (KPI-121 1 pct).  Full Article

Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 pct passive stake in Kala Pharmaceuticals Inc
Monday, 31 Jul 2017 

July 31 (Reuters) - Kala Pharmaceuticals Inc ::Hadley Harbor Master Investors (Cayman) L.P. reports 7.45 percent passive stake in Kala Pharmaceuticals Inc as on July 20, 2017 - Sec Filing‍​.  Full Article

Kala Pharma sees IPO of 6 mln shares priced between $14-$16/shr
Monday, 10 Jul 2017 

July 10 (Reuters) - Kala Pharmaceuticals Inc ::Kala Pharmaceuticals sees IPO of 6 million shares of co's common stock priced between $14.00 and $16.00 per share.  Full Article

BRIEF-Orbimed Advisors Reports About 11 Pct Passive Stake In Kala Pharmaceuticals

* ORBIMED ADVISORS LLC REPORTS ABOUT 11 PERCENT PASSIVE STAKE IN KALA PHARMACEUTICALS INC AS OF JAN 10 Source text: (http://bit.ly/2DaEc0a) Further company coverage: